"The company was informed by the USFDA that the agency placed its phase 2/3 immuno-bridging and broadening study for Covaxin (BBV152), OCU-002, on clinical hold," Ocugen said in a statement.
from Top Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/qSVOsme
Home »
Top Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com
» US asks Bharat Bio partner Ocugen to halt Covaxin trials
https://ift.tt/2YxDHWN
No comments:
Post a Comment